NCT04119024 2026-03-17Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsStanford UniversityPhase 1 Recruiting18 enrolled
NCT01204476 2016-07-15Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaNational Cancer Institute (NCI)Phase 1 Completed27 enrolled